Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

Clinical trial NCT06124378 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06124378
Sponsor: First Affiliated Hospital of Guangxi Medical University
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Colonic Neoplasms Neoadjuvant Therapy Immune Checkpoint Inhibitors

Start date: 2023-11-13
Primary completion: 2025-02-28
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.